3Helix CHP Indication: Pancreatic Ductal Adenocarcinoma (PDAC)
Bind PDAC Desmoplasia with CHPs
Introduction
3Helix Collagen Hybridizing Peptides (CHPs) are short peptides that selectively target damaged and remodeling collagen for applications in therapeutics, cosmetics, drug delivery systems, and life science tools.
Summary
Pancreatic Ductal Adenocarcinoma (PDAC) Indication: Quantify changes in collagen content in Pancreatic Ductal Adenocarcinoma (PDAC) research models with Collagen Hybridizing Peptides (CHPs) to assess stromal-targeted therapies, desmoplastic growth, and PDAC metastasis.
Indication Note
Unlock the secrets of PDAC's fibrotic stroma with Collagen Hybridizing Peptides.
Accurately mapping collagen distribution and changes within the TME is crucial for effective interrogation of PDAC tumors. PDAC is notoriously challenging to treat due to its dense, collagen-rich desmoplastic stroma, which creates a barrier to immune cell infiltration, hindering drug delivery and promoting tumor progression.
- Precisely map collagen distribution and degradation within the PDAC microenvironment, revealing critical insights into tumor desmoplasia and invasion.
- Quantify collagen changes in response to therapeutic interventions, providing a powerful tool for optimizing treatment combinations for PDAC.
- Visualize the spatial relationships between collagen and other key TME components such as CAFs and immune cells to understand their complex interactions.
Ilex Life Sciences LLC is an authorized distributor of CHP products manufactured by 3Helix, Inc.